Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

The Siren’s Curse left riders in a vertical position for about 10 minutes on June 28, the Akron Beacon Journal reported.

"Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so," ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

A Detroit man’s last wish was fulfilled as a helicopter dropped money and rose petals over part of the Motor City. Darrell ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.